-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Celldex Therapeutics, Raises Price Target to $100

Benzinga·07/20/2026 12:10:34
语音播报
Guggenheim analyst Yatin Suneja maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $90 to $100.